Studies have also shown that PTEN deficiency promotes resistance to anti‐PD1 [23] and anti‐CTLA4 [54] therapies and that inhibition of the PIK3/AKT pathway in PTEN‐deficient tumor cells could overcome the immunosuppressive tumor phenotype and the resistance to immune checkpoint inhibitors [54]. The gene discussed is CTLA4; the disease is neoplasm.